{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,7]],"date-time":"2026-09-07T11:38:00Z","timestamp":1788781080845,"version":"build-2803163510"},"reference-count":15,"publisher":"American Medical Association (AMA)","issue":"4","content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["JAMA Cardiol"],"published-print":{"date-parts":[[2026,4,1]]},"abstract":"<jats:sec id=\"ab-hbr260002-4\">\n                    <jats:title>Importance<\/jats:title>\n                    <jats:p>Transcatheter closure of patent foramen ovale (PFO) is a definitive therapy to prevent recurrent ischemic events in patients with PFO-associated embolism. However, very long-term outcome data remain scarce; these data are essential to fully understand the enduring safety and efficacy of this therapy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260002-5\">\n                    <jats:title>Objective<\/jats:title>\n                    <jats:p>To assess the 20-year clinical outcomes following PFO closure in patients with PFO-associated embolism.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260002-6\">\n                    <jats:title>Design, Setting, and Participants<\/jats:title>\n                    <jats:p>This single-center cohort study with prospective procedure, early follow-up data collection, and retrospective long-term follow-up took place at a tertiary university hospital. The study included 130 consecutive patients who had PFO closure for cryptogenic stroke, transient ischemic attack (TIA), or peripheral embolism between 2001 and 2006. These data were analyzed from February 2025 to June 2025.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260002-7\">\n                    <jats:title>Exposure<\/jats:title>\n                    <jats:p>All PFO closure procedures were technically successful and echocardiographic follow-up was performed within 1 to 6 months.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260002-8\">\n                    <jats:title>Main Outcomes and Measures<\/jats:title>\n                    <jats:p>Long-term clinical outcomes were assessed via medical record review and telephone interviews.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260002-9\">\n                    <jats:title>Results<\/jats:title>\n                    <jats:p>\n                      Mean (SD) age of the study population was 46 (14) years, with 67 women (51.5%) and 63 men (48.5%). Follow-up was complete for all but 5 patients (3.8%). At 20-year follow-up, a total of 20 patients (15.3%) had died (noncardiovascular causes in 12.2%) and recurrent ischemic events were infrequent (1 stroke [0.04 per 100 patients, per year] and 6 TIAs [0.25 per 100 patients, per year]). There was a higher prevalence of thrombophilia among patients who had recurrent ischemic events (33% vs 4.8%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04). Up to 20.5% of patients discontinued antithrombotic treatment and none of them had any ischemic event at follow-up. Bleeding events occurred in 17 patients (13%) with 9 cases (6.9%) classified as major. These events were more frequent in women (19.4% vs 6.3%;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.03) and occurred exclusively in patients receiving long-term antithrombotic therapy (17% vs 0% in patients who discontinued antithrombotic treatment;\n                      <jats:italic toggle=\"yes\">P<\/jats:italic>\n                      \u2009=\u2009.04).\n                    <\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec id=\"ab-hbr260002-10\">\n                    <jats:title>Conclusions and Relevance<\/jats:title>\n                    <jats:p>The results of this cohort study with 20-year follow-up showed the sustained very long-term safety and efficacy of transcatheter PFO closure, with less than 1% rate of recurrent stroke events. However, bleeding events occurred in about 1 in 10 patients and were more frequent in women and in patients under long-term antithrombotic therapy. These findings underscore the need for tailored long-term antithrombotic strategies after PFO closure. Further studies are warranted.<\/jats:p>\n                  <\/jats:sec>","DOI":"10.1001\/jamacardio.2026.0020","type":"journal-article","created":{"date-parts":[[2026,2,25]],"date-time":"2026-02-25T16:30:30Z","timestamp":1772037030000},"page":"383","source":"Crossref","is-referenced-by-count":3,"title":["Twenty-Year Follow-Up After Patent Foramen Ovale Closure in Patients With Paradoxical Embolism"],"prefix":"10.1001","volume":"11","author":[{"given":"Pablo","family":"Vidal-Cal\u00e9s","sequence":"first","affiliation":[{"name":"Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Christine","family":"Houde","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Quentin","family":"Battistolo","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pierre Olivier","family":"Sirois","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Laurent","family":"Desjardins","sequence":"additional","affiliation":[{"name":"Department of Pediatric Cardiology, Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Steve","family":"Verreault","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ariane","family":"Mackey","sequence":"additional","affiliation":[{"name":"Department of Neurology, Centre Hospitalier Universitaire de Qu\u00e9bec, Qu\u00e9bec, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Marilyn","family":"Labrie","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hotel Dieu de L\u00e9vis, L\u00e9vis, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Donald","family":"Rivest","sequence":"additional","affiliation":[{"name":"Department of Neurology, Hotel Dieu de L\u00e9vis, L\u00e9vis, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michel","family":"Beaudry","sequence":"additional","affiliation":[{"name":"Department of Neurology, H\u00f4pital de Chicoutimi, Chicoutimi, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M\u00e9lanie","family":"C\u00f4t\u00e9","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Josep","family":"Rod\u00e9s-Cabau","sequence":"additional","affiliation":[{"name":"Department of Cardiology, Quebec Heart and Lung Institute, Laval University, Qu\u00e9bec City, Qu\u00e9bec, Canada"},{"name":"Department of Research and Innovation, Cl\u00ednic Barcelona, Barcelona, Spain"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"10","reference":[{"issue":"8","key":"hbr260002r1","doi-asserted-by":"publisher","first-page":"907","DOI":"10.1016\/j.jacc.2015.12.023","article-title":"Device closure of patent foramen ovale after stroke: pooled analysis of completed randomized trials.","volume":"67","author":"Kent","year":"2016","journal-title":"J Am Coll Cardiol"},{"issue":"5","key":"hbr260002r2","doi-asserted-by":"publisher","first-page":"441","DOI":"10.1067\/mje.2002.116718","article-title":"Interobserver and intraobserver variability in detection of patent foramen ovale and atrial septal aneurysm with transesophageal echocardiography.","volume":"15","author":"Cabanes","year":"2002","journal-title":"J Am Soc Echocardiogr"},{"issue":"3","key":"hbr260002r3","doi-asserted-by":"publisher","first-page":"278","DOI":"10.1016\/j.jacc.2018.10.061","article-title":"Long-term follow-up after closure of patent foramen ovale in patients with cryptogenic embolism.","volume":"73","author":"Wintzer-Wehekind","year":"2019","journal-title":"J Am Coll Cardiol"},{"issue":"22","key":"hbr260002r4","doi-asserted-by":"publisher","first-page":"2315","DOI":"10.1016\/j.jcin.2022.07.044","article-title":"Supraventricular arrhythmia following patent foramen ovale percutaneous closure.","volume":"15","author":"Guedeney","year":"2022","journal-title":"JACC Cardiovasc Interv"},{"issue":"1","key":"hbr260002r5","doi-asserted-by":"publisher","first-page":"35","DOI":"10.1161\/01.STR.24.1.35","article-title":"Classification of subtype of acute ischemic stroke. Definitions for use in a multicenter clinical trial. TOAST. Trial of Org 10172 in Acute Stroke Treatment.","volume":"24","author":"Adams","year":"1993","journal-title":"Stroke"},{"issue":"23","key":"hbr260002r6","doi-asserted-by":"publisher","first-page":"2736","DOI":"10.1161\/CIRCULATIONAHA.110.009449","article-title":"Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium.","volume":"123","author":"Mehran","year":"2011","journal-title":"Circulation"},{"issue":"11","key":"hbr260002r7","doi-asserted-by":"publisher","first-page":"1011","DOI":"10.1056\/NEJMoa1705915","article-title":"Patent foramen ovale closure or anticoagulation vs. antiplatelets after stroke.","volume":"377","author":"Mas","year":"2017","journal-title":"N Engl J Med"},{"issue":"20","key":"hbr260002r8","doi-asserted-by":"publisher","first-page":"2335","DOI":"10.1016\/j.jacc.2018.02.046","article-title":"Cryptogenic stroke and high-risk patent foramen ovale: the DEFENSE-PFO Trial.","volume":"71","author":"Lee","year":"2018","journal-title":"J Am Coll Cardiol"},{"issue":"12","key":"hbr260002r9","doi-asserted-by":"publisher","first-page":"1526","DOI":"10.1016\/j.jcin.2025.04.041","article-title":"15-Year outcomes of PFO closure in patients with cryptogenic embolism: insights from the PROLONG Registry.","volume":"18","author":"Gaspardone","year":"2025","journal-title":"JACC Cardiovasc Interv"},{"key":"hbr260002r10","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1016\/j.ijcard.2022.09.033","article-title":"Real world long-term outcomes among adults undergoing transcatheter patent foramen closure with amplatzer PFO occluder.","volume":"371","author":"Abrahamyan","year":"2023","journal-title":"Int J Cardiol"},{"key":"hbr260002r11","doi-asserted-by":"publisher","DOI":"10.3389\/fneur.2020.561938","article-title":"The heart-brain team approach in patent foramen ovale closure.","volume":"11","author":"Collado","year":"2020","journal-title":"Front Neurol"},{"issue":"9","key":"hbr260002r12","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.124.034249","article-title":"Atrial fibrillation after patent foramen ovale closure: incidence, pathophysiology, and management.","volume":"13","author":"Apostolos","year":"2024","journal-title":"J Am Heart Assoc"},{"issue":"9","key":"hbr260002r13","doi-asserted-by":"publisher","first-page":"1538","DOI":"10.1016\/j.amjcard.2019.01.043","article-title":"Impact of discontinuation of antithrombotic therapy following closure of patent foramen ovale in patients with cryptogenic embolism.","volume":"123","author":"Wintzer-Wehekind","year":"2019","journal-title":"Am J Cardiol"},{"issue":"11","key":"hbr260002r14","doi-asserted-by":"publisher","DOI":"10.1161\/CIRCINTERVENTIONS.124.014467","article-title":"Sex-based differences in long-term outcomes following transcatheter closure of patent foramen ovale for cryptogenic stroke.","volume":"17","author":"Flores-Umanzor","year":"2024","journal-title":"Circ Cardiovasc Interv"},{"issue":"19","key":"hbr260002r15","doi-asserted-by":"publisher","DOI":"10.1161\/JAHA.123.030359","article-title":"Sex differences in patients with cryptogenic cerebrovascular events undergoing transcatheter closure of patent foramen ovale.","volume":"12","author":"Farjat-Pasos","year":"2023","journal-title":"J Am Heart Assoc"}],"container-title":["JAMA Cardiology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/articlepdf\/2845593\/jamacardiology_vidalcals_2026_br_260002_1775567402.3879.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,8]],"date-time":"2026-04-08T15:00:44Z","timestamp":1775660444000},"score":1,"resource":{"primary":{"URL":"https:\/\/jamanetwork.com\/journals\/jamacardiology\/fullarticle\/2845593"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,1]]},"references-count":15,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2026,4,1]]}},"URL":"https:\/\/doi.org\/10.1001\/jamacardio.2026.0020","relation":{},"ISSN":["2380-6583"],"issn-type":[{"value":"2380-6583","type":"print"}],"subject":[],"published":{"date-parts":[[2026,4,1]]}}}